Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Differential expression of angiogenic cytokines by cell lines and primary cultures of human prostate cancer

Prostate Cancer and Prostatic Diseases volume 4, pages 106–111 (2001)Cite this article

Abstract

Studies on angiogenic cytokines usually are initially based upon their expression by available established cell lines. Our hypothesis is that established epithelial prostate cancer (CaP) cell lines do not accurately reflect angiogenic cytokine expression as compared to epithelial and stromal components of primary cultures generated from clinical CaP specimens. Serum free and growth factor free conditioned medium (CM) was collected from PC3, LNCaP, and their orthotopic selected prostate cancer sublines. Surgically acquired and pathologically confirmed neoplastic prostate tissue was selectively grown for selection of epithelial or stromal components, and CM was also collected. CM was assayed for urokinase (u-PA), basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), and tumor necrosis factor alpha (TNF-α). u-PA was expressed only by androgen independent cell lines, but was detectable in the epithelial and stromal cultures of androgen sensitive primary cultures. bFGF was not secreted by cell lines nor epithelial primary cultures. VEGF was universally expressed, but TNF-α was not secreted by cells lines nor primary cultures. These data suggest that the expression of angiogenic cytokines by established epithelial CaP cell lines does not reflect epithelial and stromal primary cultures.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Folkman J, Shing J. Angiogenesis. J Biol Chem 1992 267 10931–10934.

    CAS  PubMed  Google Scholar 

  2. Ausprunk DH, Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvascular Research 1977 14 53–65.

    Article  CAS  PubMed  Google Scholar 

  3. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987 235 442–447.

    Article  CAS  PubMed  Google Scholar 

  4. Goto F, Goto K, Weindel K, Folkman J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest 1993 69 509–517.

    Google Scholar 

  5. Mandriota SJ et al Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 1995 270 9709–9716.

    Article  CAS  PubMed  Google Scholar 

  6. Pepper MS, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991 181 902–906.

    Article  CAS  PubMed  Google Scholar 

  7. Dvorak HG, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995 146 1029–1039.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Yoshida A, Anand-Apte B, Zetter BR. Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. Growth Factors 1996 13 57–64.

    Article  CAS  PubMed  Google Scholar 

  9. Kumar R, Yoneda J, Bucana CD, Fidler IJ. Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int J Oncol 1998 12 749–757.

    CAS  PubMed  Google Scholar 

  10. Melnyk O, Zimmerman M, Kim JK, Shuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol 1999 161 960–963.

    Article  CAS  PubMed  Google Scholar 

  11. Ferrer FA et al Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997 157 2329–2333.

    Article  CAS  PubMed  Google Scholar 

  12. Jackson MW, Bentel JM, Tilley WD. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 1997 157 2323–2328.

    Article  CAS  PubMed  Google Scholar 

  13. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro Biochem Biophys Res Commun 1992 189 824–831.

    Article  CAS  PubMed  Google Scholar 

  14. Sato Y, Rifkin DB. Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol 1988 107 1199–1205.

    Article  CAS  PubMed  Google Scholar 

  15. Rifkin DB, Moscatelli D. Recent developments in the cell biology of basic fibroblast growth factor. J Cell Biol 1989 106 1–6.

    Article  Google Scholar 

  16. Takahashi JA et al Inhibition of cell growth and tumorigenesis of human gliolastoma cells by a neutralizing antibody against human basic fibroblast growth factor. FEBS Lett 1991 288 65–71.

    Article  CAS  PubMed  Google Scholar 

  17. Giri D, Ropiquet F, Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 1999 5 1063–1071.

    CAS  PubMed  Google Scholar 

  18. Presta M, Moscatelli D, Joseph-Silverstein J, Rifkin DB. Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molcecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration. Mol Cell Biol 1986 6 4060–4066.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Frater-Schroder M et al Tumor necrosis factor type-α, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo Proc Natl Acad Sci, USA 1987 84 5277–5281.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Niedbala MJ, Stein M. Tumor necrosis factor induction of urokinase-type plasminogen activator in human endothelial cells. Biomed Biochim Acta 1991 50 427–436.

    CAS  PubMed  Google Scholar 

  21. Koolwijk P et al Cooperative effect of TNFα, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol 1996 132 1177–1188.

    Article  CAS  PubMed  Google Scholar 

  22. Gaylis FD et al Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. J Urol 1989 142 193–198.

    Article  CAS  PubMed  Google Scholar 

  23. Hollas W et al Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thrombosis and Haemostasis 1992 68 662–666.

    Article  CAS  PubMed  Google Scholar 

  24. Van Veldhuizen PJ, Sadasivan R, Cherian R, Wyatt A. Urokinase-type plasminogen activator expression in human prostate carcinomas. Am J Med Sci 1996 312 8–11.

    Article  CAS  PubMed  Google Scholar 

  25. Pepper MS et al Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein 1996 49 138–162.

    Article  CAS  PubMed  Google Scholar 

  26. Evans CP et al Inhibition of prostate cancer neovascularization and growth by urokinase-type plasminogen activator receptor blockade. Cancer Res. 1997 57 3594–3599.

    CAS  PubMed  Google Scholar 

  27. Pettaway CA et al Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 1996 2 1627–1636.

    CAS  PubMed  Google Scholar 

  28. Nakamoto T, Chang C, Li A, Chodak GW. Basic fibroblast growth factor in human prostate cancer cells. Cancer Res 1992 52 571–577.

    CAS  PubMed  Google Scholar 

  29. Folkman J et al Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989 339 58–61.

    Article  CAS  PubMed  Google Scholar 

  30. Gimbrone MA Jr, Cotran RS, Leapman SB, Folkman J. Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst 1974 52 413–427.

    Article  PubMed  Google Scholar 

  31. Weidner N et al Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Path 1993 143 401–409.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Fregene T et al Tumor-associated angiogenesis in prostate cancer. Anticancer Res 1993 13 2377–2381.

    CAS  PubMed  Google Scholar 

  33. Potgens AJG, Westphal HR, de Waal RMW, Ruiter DJ. The role of vascular permeability factor and basic fibroblast growth factor in tumor angiogenesis. Biol Chem 1995 376 57–70.

    CAS  Google Scholar 

  34. Joseph IBJK, Isaacs JT. Potentiation of the anti-angiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen responsive prostatic cancers. Cancer Res 1997 57 1054–1057.

    CAS  PubMed  Google Scholar 

  35. Balbay MD et al Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Clin Cancer Res 1999 5 783–789.

    CAS  PubMed  Google Scholar 

  36. Dano K et al Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985 44 139.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Dr Donna Peehl (Stanford University) for her invaluable assistance with protocols for establishing primary prostate cultures. This research was supported by the University of California, Davis Health System Research Award, American Cancer Society Institutional Research Award no. 205.

Author information

Authors and Affiliations

  1. Department of Urology, University of California, Davis School of Medicine, Sacramento, CA, USA

    MA Dall'Era, S-J Shih, J Yang, S Benik & CP Evans

  2. Department of Pathology, University of California, Davis School of Medicine, Sacramento, CA, USA

    R Gandour-Edwards

Authors
  1. MA Dall'Era
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S-J Shih
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Benik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Gandour-Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. CP Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to CP Evans.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dall'Era, M., Shih, SJ., Yang, J. et al. Differential expression of angiogenic cytokines by cell lines and primary cultures of human prostate cancer. Prostate Cancer Prostatic Dis 4, 106–111 (2001). https://doi.org/10.1038/sj.pcan.4500515

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500515

Keywords

This article is cited by

Search

Advanced search

Quick links